Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

OBJECTIVES: In the ‘Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism’ (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: de Jong, Lisa A, van der Velden, Annette W G, van Hulst, Marinus, Postma, Maarten J
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Health Economics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7678368/
https://ncbi.nlm.nih.gov/pubmed/33444193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-039057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars